Kyntra Bio, Inc.
KYNB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000921299
No open-market purchases or sales by Kyntra Bio, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $7.54M in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Kyntra Bio, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 176
- −22 vs. Q1 2021
- Shares held
- 67.7M
- −2.99M (−4.2%) vs. Q1 2021
- Total value
- $1.80B
- −$650.6M (−26.5%) vs. Q1 2021
- New holders
- 33
- 55 more added
- Sold out
- 55
- 55 more reduced
1 institution that held it in Q1 2021 haven't filed for Q2 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KYNB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 27 | $7.54M |
| Q1 2026 | 32 | $7.01M |
| Q4 2025 | 34 | $10.1M |
| Q3 2025 | 32 | $13.9M |
| Q2 2025 | 30 | $5.62M |
| Q1 2025 | 56 | $10.2M |
| Q4 2024 | 70 | $19.2M |
| Q3 2024 | 72 | $18.3M |
| Q2 2024 | 102 | $50.4M |
| Q1 2024 | 111 | $143.9M |
| Q4 2023 | 100 | $62.1M |
| Q3 2023 | 110 | $59.0M |
| Q2 2023 | 153 | $207.9M |
| Q1 2023 | 173 | $1.42B |
| Q4 2022 | 145 | $1.20B |
| Q3 2022 | 152 | $950.1M |
| Q2 2022 | 152 | $746.9M |
| Q1 2022 | 158 | $816.6M |
| Q4 2021 | 164 | $934.6M |
| Q3 2021 | 165 | $656.8M |
| Q2 2021 | 176 | $1.80B |
| Q1 2021 | 199 | $2.47B |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Kyntra Bio, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Paloma Partners Management Co | 0 | $0 | 0.00% | −14,262−100.0% | Sold out |
| Pearl River Capital, LLC | 0 | $0 | 0.00% | −13,787−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −11,848−100.0% | Sold out |
| Oppenheimer Asset Management Inc. | 0 | $0 | 0.00% | −9,435−100.0% | Sold out |
| Glenmede Trust Co NA | 0 | $0 | 0.00% | −7,545−100.0% | Sold out |
| CIBC Private Wealth Group, LLC | 0 | $0 | 0.00% | −7,201−100.0% | Sold out |
| EFG Asset Management (Americas) Corp. | 0 | $0 | 0.00% | −7,143−100.0% | Sold out |
| BBR Partners, LLC | 0 | $0 | 0.00% | −7,056−100.0% | Sold out |
| Quantbot Technologies LP | 0 | $0 | 0.00% | −6,687−100.0% | Sold out |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −6,537−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −6,513−100.0% | Sold out |
| Dowling & Yahnke LLC | 0 | $0 | 0.00% | −6,453−100.0% | Sold out |
| Donoghue Forlines LLC | 0 | $0 | 0.00% | −6,341−100.0% | Sold out |
| Cambridge Investment Research Advisors, Inc. | 0 | $0 | 0.00% | −6,000−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −6,000−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −7,650−100.0% | Sold out |
| FORA Capital, LLC | 0 | $0 | 0.00% | −2,410−100.0% | Sold out |
| Pacer Advisors, Inc. | 0 | $0 | 0.00% | −2,210−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −1,752−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −2,292−100.0% | Sold out |
| Fieldpoint Private Securities, LLC | 0 | $0 | 0.00% | −1,366−100.0% | Sold out |
| Axiom Investment Management LLC | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Lindbrook Capital, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Valeo Financial Advisors, LLC | 0 | $0 | 0.00% | −400−100.0% | Sold out |
| First Horizon Advisors, Inc. | 0 | $0 | 0.00% | −359−100.0% | Sold out |
| Phoenix Wealth Advisors | 0 | $0 | 0.00% | −200−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −48−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −35−100.0% | Sold out |
| Assetmark, Inc | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| International Assets Investment Management, LLC | 0 | $0 | 0.00% | −10−100.0% | Sold out |
| Alpha DNA Investment Management LLC | 0 | $0 | 0.00% | −25−100.0% | Sold out |
| Amundi Asset Management US, Inc. | – | – | – | – | Not filed |